Mitochondrial neuroprotection in traumatic brain injury: Rationale and therapeutic strategies

Shoji Yokobori, Anna T. Mazzeo, Shyam Gajavelli, Ross Bullock

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is still the worldwide, leading cause of mortality and morbidity in young adults. The prognosis of TBI patients is strongly affected by secondary brain damage including mitochondrial dysfunctions. In many basic and clinical studies, mitochondrial dysfunctions, including the opening of mitochondrial permeability transition (mPT) pore, and treatments including cyclosporine A (CsA) have been studied. These evidences suggest an important role for mitochondria as therapeutic targets for neuroprotection after TBI. This review summarizes the data about normal and pathological mitochondrial function after TBI, TBI pathobiology relating to mitochondrial dysfunction and therapeutic strategies including drug treatment. This review also mentioned about glucose, lactate, and pyruvate metabolisms in TBI, including the astrocyte-neuron lactate shuttle (ANLS) hypothesis. Mitochondrial pathophysiology in TBI is still unclear. Thus, the pharmacological treatment in TBI patient is still challenging. This review could help further understanding of this topic. Hopefully, this could help further development and innovation for drug therapies in TBI.

Original languageEnglish
Pages (from-to)606-619
Number of pages14
JournalCNS and Neurological Disorders - Drug Targets
Volume13
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Therapeutics
Lactic Acid
Traumatic Brain Injury
Neuroprotection
Pyruvic Acid
Astrocytes
Cyclosporine
Young Adult
Mitochondria
Pharmacology
Morbidity
Neurons
Glucose
Drug Therapy
Mortality
Brain
Pharmaceutical Preparations
Clinical Studies
mitochondrial permeability transition pore

Keywords

  • Apoptosis
  • Astrocyte-neuron lactate shuttle
  • Cyclosporine A
  • Mitochondrial dysfunction
  • Mitochondrial permeability transition pore
  • Secondary brain injury
  • Traumatic brain injury

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Mitochondrial neuroprotection in traumatic brain injury : Rationale and therapeutic strategies. / Yokobori, Shoji; Mazzeo, Anna T.; Gajavelli, Shyam; Bullock, Ross.

In: CNS and Neurological Disorders - Drug Targets, Vol. 13, No. 4, 01.01.2014, p. 606-619.

Research output: Contribution to journalArticle

Yokobori, Shoji ; Mazzeo, Anna T. ; Gajavelli, Shyam ; Bullock, Ross. / Mitochondrial neuroprotection in traumatic brain injury : Rationale and therapeutic strategies. In: CNS and Neurological Disorders - Drug Targets. 2014 ; Vol. 13, No. 4. pp. 606-619.
@article{82aa8e0754ec4352820c6f481a9dd9e0,
title = "Mitochondrial neuroprotection in traumatic brain injury: Rationale and therapeutic strategies",
abstract = "Traumatic brain injury (TBI) is still the worldwide, leading cause of mortality and morbidity in young adults. The prognosis of TBI patients is strongly affected by secondary brain damage including mitochondrial dysfunctions. In many basic and clinical studies, mitochondrial dysfunctions, including the opening of mitochondrial permeability transition (mPT) pore, and treatments including cyclosporine A (CsA) have been studied. These evidences suggest an important role for mitochondria as therapeutic targets for neuroprotection after TBI. This review summarizes the data about normal and pathological mitochondrial function after TBI, TBI pathobiology relating to mitochondrial dysfunction and therapeutic strategies including drug treatment. This review also mentioned about glucose, lactate, and pyruvate metabolisms in TBI, including the astrocyte-neuron lactate shuttle (ANLS) hypothesis. Mitochondrial pathophysiology in TBI is still unclear. Thus, the pharmacological treatment in TBI patient is still challenging. This review could help further understanding of this topic. Hopefully, this could help further development and innovation for drug therapies in TBI.",
keywords = "Apoptosis, Astrocyte-neuron lactate shuttle, Cyclosporine A, Mitochondrial dysfunction, Mitochondrial permeability transition pore, Secondary brain injury, Traumatic brain injury",
author = "Shoji Yokobori and Mazzeo, {Anna T.} and Shyam Gajavelli and Ross Bullock",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/187152731304140702112805",
language = "English",
volume = "13",
pages = "606--619",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Mitochondrial neuroprotection in traumatic brain injury

T2 - Rationale and therapeutic strategies

AU - Yokobori, Shoji

AU - Mazzeo, Anna T.

AU - Gajavelli, Shyam

AU - Bullock, Ross

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Traumatic brain injury (TBI) is still the worldwide, leading cause of mortality and morbidity in young adults. The prognosis of TBI patients is strongly affected by secondary brain damage including mitochondrial dysfunctions. In many basic and clinical studies, mitochondrial dysfunctions, including the opening of mitochondrial permeability transition (mPT) pore, and treatments including cyclosporine A (CsA) have been studied. These evidences suggest an important role for mitochondria as therapeutic targets for neuroprotection after TBI. This review summarizes the data about normal and pathological mitochondrial function after TBI, TBI pathobiology relating to mitochondrial dysfunction and therapeutic strategies including drug treatment. This review also mentioned about glucose, lactate, and pyruvate metabolisms in TBI, including the astrocyte-neuron lactate shuttle (ANLS) hypothesis. Mitochondrial pathophysiology in TBI is still unclear. Thus, the pharmacological treatment in TBI patient is still challenging. This review could help further understanding of this topic. Hopefully, this could help further development and innovation for drug therapies in TBI.

AB - Traumatic brain injury (TBI) is still the worldwide, leading cause of mortality and morbidity in young adults. The prognosis of TBI patients is strongly affected by secondary brain damage including mitochondrial dysfunctions. In many basic and clinical studies, mitochondrial dysfunctions, including the opening of mitochondrial permeability transition (mPT) pore, and treatments including cyclosporine A (CsA) have been studied. These evidences suggest an important role for mitochondria as therapeutic targets for neuroprotection after TBI. This review summarizes the data about normal and pathological mitochondrial function after TBI, TBI pathobiology relating to mitochondrial dysfunction and therapeutic strategies including drug treatment. This review also mentioned about glucose, lactate, and pyruvate metabolisms in TBI, including the astrocyte-neuron lactate shuttle (ANLS) hypothesis. Mitochondrial pathophysiology in TBI is still unclear. Thus, the pharmacological treatment in TBI patient is still challenging. This review could help further understanding of this topic. Hopefully, this could help further development and innovation for drug therapies in TBI.

KW - Apoptosis

KW - Astrocyte-neuron lactate shuttle

KW - Cyclosporine A

KW - Mitochondrial dysfunction

KW - Mitochondrial permeability transition pore

KW - Secondary brain injury

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84904500326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904500326&partnerID=8YFLogxK

U2 - 10.2174/187152731304140702112805

DO - 10.2174/187152731304140702112805

M3 - Article

C2 - 24168363

AN - SCOPUS:84904500326

VL - 13

SP - 606

EP - 619

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 4

ER -